Access the full text.
Sign up today, get DeepDyve free for 14 days.
F. Dicker, H. Herholz, S. Schnittger, A. Nakao, N. Patten, Lin Wu, W. Kern, T. Haferlach, C. Haferlach (2009)
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotypeLeukemia, 23
S. Kurdistani (2007)
Histone modifications as markers of cancer prognosis: a cellular viewBritish Journal of Cancer, 97
G. Lazarian, E. Tausch, V. Eclache, Amel Sebaa, Vincent Bianchi, R. Letestu, Jean-Francois Collon, V. Lefebvre, Laura Gardano, N. Varin‐Blank, T. Soussi, S. Stilgenbauer, F. Cymbalista, F. Baran-Marszak (2016)
TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypesInternational Journal of Cancer, 139
Feng Li, J. Zeng, Yang Gao, Zhenfeng guan, Zhen-kun Ma, Q. Shi, Chong Du, Jing Jia, Shan Xu, Xin-yang Wang, L. Chang, D. He, P. Guo (2015)
G9a Inhibition Induces Autophagic Cell Death via AMPK/mTOR Pathway in Bladder Transitional Cell CarcinomaPLoS ONE, 10
C. Mozzetta, Julien Pontis, S. Ait-Si-Ali (2014)
Functional Crosstalk Between Lysine Methyltransferases on Histone Substrates: The Case of G9A/GLP and Polycomb Repressive Complex 2.Antioxidants & redox signaling, 22 16
Y. Shinkai, M. Tachibana (2011)
H3K9 methyltransferase G9a and the related molecule GLP.Genes & development, 25 8
D. Roos-Weil, F. Nguyen‐Khac, O. Bernard (2016)
Chronic lymphocytic leukemia: Time to go past genomics?American Journal of Hematology, 91
H. Döhner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Kröber, L. Bullinger, K. Döhner, Martin Bentz, P. Lichter (2000)
Genomic aberrations and survival in chronic lymphocytic leukemia.The New England journal of medicine, 343 26
T. Zenz, D. Mertens, R. Küppers, H. Döhner, S. Stilgenbauer (2010)
From pathogenesis to treatment of chronic lymphocytic leukaemiaNature Reviews Cancer, 10
C. Mayr, M. Speicher, D. Kofler, R. Buhmann, J. Strehl, R. Busch, M. Hallek, C. Wendtner (2006)
Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia.Blood, 107 2
R. Guièze, Catherine Wu (2015)
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.Blood, 126 4
A. Ren, Y. Qiu, H. Cui, G. Fu (2015)
Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma.Biochemical and biophysical research communications, 459 1
S. Loh, W. Ng, K. Yeo, Yat-Yuen Lim, Chee-Kwee Ea (2014)
Inhibition of Euchromatic Histone Methyltransferase 1 and 2 Sensitizes Chronic Myeloid Leukemia Cells to Interferon TreatmentPLoS ONE, 9
K. Rai, P. Jain (2016)
Chronic lymphocytic leukemia (CLL)—Then and nowAmerican Journal of Hematology, 91
E. Koníková, J. Kusenda (2003)
Altered expression of p53 and MDM2 proteins in hematological malignancies.Neoplasma, 50 1
Xiaolei Lin, Yiqun Huang, Y. Zou, Xingsheng Chen, Xudong Ma (2016)
Depletion of G9a gene induces cell apoptosis in human gastric carcinoma.Oncology reports, 35 5
K. Rai, A. Sawitsky, E. Cronkite, A. Chanana, R. Levy, B. Pasternack (1975)
Clinical staging of chronic lymphocytic leukemia.Blood, 46 2
T. Zenz, B. Eichhorst, R. Busch, T. Denzel, Sonja Häbe, D. Winkler, A. Bühler, J. Edelmann, M. Bergmann, G. Hopfinger, M. Hensel, M. Hallek, H. Döhner, S. Stilgenbauer (2010)
TP53 mutation and survival in chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 29
J. Orchard, R. Ibbotson, Z. Davis, A. Wiestner, A. Rosenwald, P. Thomas, T. Hamblin, L. Staudt, D. Oscier (2004)
ZAP-70 expression and prognosis in chronic lymphocytic leukaemiaThe Lancet, 363
Xiao Zhang, Freya Shephard, Hong Kim, I. Palmer, Selina McHarg, Gregory Fowler, Luke O’Neill, E. Kiss-Toth, E. Qwarnstrom (2009)
TILRR, a Novel IL-1RI Co-receptor, Potentiates MyD88 Recruitment to Control Ras-dependent Amplification of NF-κB*The Journal of Biological Chemistry, 285
Binet Jl, A. Auquier, G. Dighiero, C. Chastang, H. Piguet, J. Goasguen, G. Vaugier, G. Potron, P. Colona, F. Oberling, Mark Thomas, G. Tchernia, C. Jacquillat, P. Boivin, C. Lesty, M. Duault, M. Monconduit, S. Belabbes, F. Grémy (1981)
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysisCancer, 48
J Huang, J Dorsey, S Chuikov (2010)
G9a and Glp methylate lysine 373 in the tumor suppressor p53J Biol Chem, 285
C. Nabhan, G. Raca, Y. Wang (2015)
Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.JAMA oncology, 1 7
R. Tomasini, T. Mak, G. Melino (2008)
The impact of p53 and p73 on aneuploidy and cancer.Trends in cell biology, 18 5
E. Matutes, K. Owusu‐Ankomah, R. Morilla, J. GarciaMarco, A. Houlihan, Que Th, D. Catovsky (1994)
The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.Leukemia, 8 10
M. Crespo, F. Bosch, N. Villamor, B. Bellosillo, D. Colomer, M. Rozman, S. Marcé, A. López-Guillermo, E. Campo, E. Montserrat (2003)
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.The New England journal of medicine, 348 18
L. Scarfò, A. Ferreri, P. Ghia (2016)
Chronic lymphocytic leukaemia.Critical reviews in oncology/hematology, 104
You-Syuan Lai, J-Y Chen, H. Tsai, Ty Chen, W. Hung (2015)
The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cellsBlood Cancer Journal, 5
W. Pappano, Jun Guo, Yupeng He, D. Ferguson, Sujatha Jagadeeswaran, Donald Osterling, Wenqing Gao, Julie Spence, Marina Pliushchev, R. Sweis, F. Buchanan, M. Michaelides, A. Shoemaker, Chris Tse, G. Chiang (2015)
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of LeukemiaPLoS ONE, 10
Background Heterodimeric methyltransferases GLP (EHMT1/KMT1D) and G9a (EHMT2/KMT1C) are two closely related enzymes that promote the monomethylation and dimethylation of histone H3 lysine 9. Dysregulation of their activity has been implicated in several types of human cancer. Patients and methods Here, in order to investigate whether GLP/G9a exerts any impact on Chronic Lymphocytic Leukemia (CLL), GLP/G9a expression levels were assessed in a cohort of 50 patients and the effects of their inhibition were verified for the viability of CLL cells. Also, qRT-PCR was used to investigate the transcriptional levels of GLP/G9a in CLL patients. In addition, patient samples were classified according to ZAP-70 protein expression by flow cytometry and according to karyotype integrity by cytogenetics analysis. Finally, a selective small molecule inhibitor for GLP/G9a was used to ascertain whether these methyltransferases influenced the viability of MEC-1 CLL cell lineage. Results mRNA analysis revealed that CLL samples had higher levels of GLP, but not G9a, when compared to non-leukemic controls. Interestingly, patients with unfavorable cytogenetics showed higher expression levels of GLP compared to patients with favorable karyotypes. More importantly, GLP/G9a inhibition markedly induced cell death in CLL cells. Conclusion Taken together, these results indicate that GLP is associated with a worse prognosis in CLL, and that the inhibition of GLP/G9a influences CLL cell viability. Altogether, the present data demonstrate that these methyltransferases can be potential markers for disease progression, as well as a promising epigenetic target for CLL treatment and the prevention of disease evolution.
Investigational New Drugs – Springer Journals
Published: May 31, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.